These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30377559)

  • 41. PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion.
    Qiao DR; Cheng JY; Yan WQ; Li HJ
    Clin Transl Oncol; 2023 Aug; 25(8):2373-2383. PubMed ID: 36856921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells
    Liu H; Zhou S; Liu J; Chen F; Zhang Y; Liu M; Min S; Wang H; Wang X; Wu N
    Front Oncol; 2022; 12():747482. PubMed ID: 35174079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer.
    Fasano M; Della Corte CM; Di Liello R; Barra G; Sparano F; Viscardi G; Iacovino ML; Paragliola F; Famiglietti V; Ciaramella V; Cimmino F; Capasso M; Iolascon A; Sforza V; Morabito A; Maiello E; Ciardiello F; Morgillo F
    ESMO Open; 2020 Sep; 5(5):e000753. PubMed ID: 32912860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
    Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
    Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.
    Grenga I; Donahue RN; Lepone LM; Richards J; Schlom J
    Clin Transl Immunology; 2016 May; 5(5):e83. PubMed ID: 27350882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
    Dong W; Wu X; Ma S; Wang Y; Nalin AP; Zhu Z; Zhang J; Benson DM; He K; Caligiuri MA; Yu J
    Cancer Discov; 2019 Oct; 9(10):1422-1437. PubMed ID: 31340937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor.
    Kaur K; Safaie T; Ko MW; Wang Y; Jewett A
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33440654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
    Bourhis J; Stein A; Paul de Boer J; Van Den Eynde M; Gold KA; Stintzing S; Becker JC; Moran M; Schroeder A; Pennock G; Salmio S; Esser R; Ciardiello F
    Cancer Treat Rev; 2021 Jun; 97():102172. PubMed ID: 33989949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
    Makowska A; Lelabi N; Nothbaum C; Shen L; Busson P; Tran TTB; Eble M; Kontny U
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HDAC inhibitors enhance the immunotherapy response of melanoma cells.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Dent P
    Oncotarget; 2017 Oct; 8(47):83155-83170. PubMed ID: 29137331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
    Gatti-Mays ME; Gameiro SR; Ozawa Y; Knudson KM; Hicks KC; Palena C; Cordes LM; Steinberg SM; Francis D; Karzai F; Lipkowitz S; Donahue RN; Jochems C; Schlom J; Gulley JL
    Front Oncol; 2020; 10():581801. PubMed ID: 33747894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model.
    Kim Y; Park K; Kim YJ; Shin SW; Kim YJ; Choi C; Noh JM
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
    Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.